Skip to main content
main-content

01.07.2008 | Original Contribution | Ausgabe 7/2008

Diseases of the Colon & Rectum 7/2008

Fistula-Associated Anal Adenocarcinoma: Good Results with Aggressive Therapy

Zeitschrift:
Diseases of the Colon & Rectum > Ausgabe 7/2008
Autoren:
M.D. Wolfgang B. Gaertner, M.D. Gonzalo F. Hagerman, M.D. Charles O. Finne, M.D. Karim Alavi, M.D. Jose Jessurun, M.D. David A. Rothenberger, M.D. Robert D. Madoff
Wichtige Hinweise
The authors have no relative financial disclosures to report.
Poster presentation at the meeting of The American College of Surgeons, New Orleans, Louisiana, October 7 to 11, 2007.

Abstract

Purpose

To evaluate the clinical features, pathology, treatment, and outcome of patients with fistula-associated anal adenocarcinoma.

Methods

We identified 14 patients with histologically proven fistula-associated anal adenocarcinoma. We reviewed their medical records and pathology specimens to characterize their presentation, treatment, and clinical outcome.

Results

Nine patients presented with a persistent fistula, 3 with a perianal mass, 1 with pain and drainage, and 1 with a recurrent perianal abscess. The average age at time of diagnosis was 59 (range, 37–76) years. Eleven patients had preexisting chronic anal fistulas. Ten had Crohn’s disease, and 1 had previously received pelvic radiation therapy. The diagnosis of cancer was suspected during physical examination in 6 of the 14 patients (43 percent). Twelve patients had extensive local disease at presentation. Primary abdominoperineal resection was performed in 11 patients, 7 following neoadjuvant chemoradiation. Six patients received postoperative chemotherapy, and 2 received postoperative radiation. Four patients died with metastatic disease. The remaining 10 patients are alive without evidence of disease at a mean follow-up of 64.3 (range, 14–149) months.

Conclusions

The diagnosis of fistula-associated anal adenocarcinoma is often unsuspected. Most patients can be cured with aggressive surgical and adjuvant chemoradiotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2008

Diseases of the Colon & Rectum 7/2008 Zur Ausgabe

Letter to the Editor

The Authors Reply

  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise